Potassium-competitive acid blockers and acid-related disorders.

IF 2.6 3区医学 Q3 ENDOCRINOLOGY & METABOLISM Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2024-06-01 Epub Date: 2024-03-14 DOI:10.1097/MED.0000000000000858

Kevin Z Huang, H Christian Weber

{"title":"Potassium-competitive acid blockers and acid-related disorders.","authors":"Kevin Z Huang, H Christian Weber","doi":"10.1097/MED.0000000000000858","DOIUrl":null,"url":null,"abstract":"Purpose of review: Potassium-competitive acid blockers (PCABs) represent a new class of compounds for the treatment of acid-related disorders. Recent FDA approval of the PCAB vonoprazan for erosive esophagitis has started an important new approach to acid-related disorders.Recent findings: Compared to conventional proton pump inhibitors (PPIs), PCABs provide more rapid, potent, and sustained suppression of gastric acid with faster and more durable symptom relief. Studies have demonstrated the efficacy of PCABs for erosive esophagitis, nonerosive reflux disease, and peptic ulcer disease including H. pylori. However, the PCAB vonoprazan was only approved in the US as part of combination therapy for eradication of H. pylori. Clinical trials have now demonstrated noninferiority of vonoprazan to lansoprazole for treatment of erosive esophagitis, particularly noting superiority of vonoprazan in patients with severe esophagitis resulting in FDA approval of vonoprazan for treatment of erosive esophagitis. Emerging data suggests a possible utility of vonoprazan for PPI-resistant gastroesophageal reflux disease (GERD) and on-demand therapy for nonerosive reflux disease. Vonoprazan is generally well tolerated but long-term safety data is not well established.Summary: The PCAB vonoprazan is a newly FDA approved treatment option for erosive esophagitis. Its possible role in PPI-resistant GERD and nonerosive reflux disease warrants further investigation.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Endocrinology & Diabetes and Obesity","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MED.0000000000000858","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Potassium-competitive acid blockers (PCABs) represent a new class of compounds for the treatment of acid-related disorders. Recent FDA approval of the PCAB vonoprazan for erosive esophagitis has started an important new approach to acid-related disorders.

Recent findings: Compared to conventional proton pump inhibitors (PPIs), PCABs provide more rapid, potent, and sustained suppression of gastric acid with faster and more durable symptom relief. Studies have demonstrated the efficacy of PCABs for erosive esophagitis, nonerosive reflux disease, and peptic ulcer disease including H. pylori. However, the PCAB vonoprazan was only approved in the US as part of combination therapy for eradication of H. pylori. Clinical trials have now demonstrated noninferiority of vonoprazan to lansoprazole for treatment of erosive esophagitis, particularly noting superiority of vonoprazan in patients with severe esophagitis resulting in FDA approval of vonoprazan for treatment of erosive esophagitis. Emerging data suggests a possible utility of vonoprazan for PPI-resistant gastroesophageal reflux disease (GERD) and on-demand therapy for nonerosive reflux disease. Vonoprazan is generally well tolerated but long-term safety data is not well established.

Summary: The PCAB vonoprazan is a newly FDA approved treatment option for erosive esophagitis. Its possible role in PPI-resistant GERD and nonerosive reflux disease warrants further investigation.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

钾竞争性酸阻滞剂与酸相关疾病。

综述的目的：钾竞争性酸阻滞剂（PCABs）是治疗酸相关疾病的一类新型化合物。最近，美国食品及药物管理局批准 PCAB vonoprazan 用于治疗侵蚀性食管炎，开启了治疗酸相关疾病的重要新方法：与传统的质子泵抑制剂（PPIs）相比，PCABs 能更快速、有效、持续地抑制胃酸，更快、更持久地缓解症状。研究表明，PCAB 对侵蚀性食管炎、非侵蚀性反流病和包括幽门螺杆菌在内的消化性溃疡病具有疗效。然而，美国只批准将 PCAB vonoprazan 作为根除幽门螺杆菌的联合疗法的一部分。临床试验现已证明，在治疗侵蚀性食管炎方面，vonoprazan 的疗效并不亚于兰索拉唑，尤其是在治疗严重食管炎患者方面，vonoprazan 的疗效更胜一筹，因此 FDA 批准 vonoprazan 用于治疗侵蚀性食管炎。新的数据表明，vonoprazan 可用于治疗耐 PPI 胃食管反流病（GERD）和按需治疗非侵蚀性反流病。Vonoprazan一般耐受性良好，但长期安全性数据尚未完全确定。摘要：PCAB vonoprazan是FDA新近批准的一种治疗侵蚀性食管炎的药物。它在耐 PPI 胃食管反流病和非侵蚀性反流病中可能发挥的作用值得进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Opinion in Endocrinology & Diabetes and Obesity ENDOCRINOLOGY & METABOLISM-

CiteScore

5.80

自引率

3.10%

发文量

128

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Endocrinology, Diabetes and Obesity delivers a broad-based perspective on the most recent and exciting developments in the field from across the world. Published bimonthly and featuring twelve key topics – including androgens, gastrointestinal hormones, diabetes and the endocrine pancreas, and neuroendocrinology – the journal’s renowned team of guest editors ensure a balanced, expert assessment of the recently published literature in each respective field with insightful editorials and on-the-mark invited reviews.

期刊最新文献

Editorial introduction. Predictors of cardiovascular risk in familial hypercholesterolemia. TSHR-IGF-IR complex drives orbital fibroblast misbehavior in thyroid eye disease. Epidemiologic changes in thyroid disease. Indications for testosterone therapy in men.